Telix Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Telix Pharmaceuticals has a total shareholder equity of A$148.9M and total debt of A$9.2M, which brings its debt-to-equity ratio to 6.2%. Its total assets and total liabilities are A$398.3M and A$249.4M respectively. Telix Pharmaceuticals's EBIT is A$51.9M making its interest coverage ratio -220.8. It has cash and short-term investments of A$123.2M.
Key information
6.2%
Debt to equity ratio
AU$9.17m
Debt
Interest coverage ratio | -220.8x |
Cash | AU$123.24m |
Equity | AU$148.91m |
Total liabilities | AU$249.39m |
Total assets | AU$398.30m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: TLX's short term assets (A$224.8M) exceed its short term liabilities (A$157.4M).
Long Term Liabilities: TLX's short term assets (A$224.8M) exceed its long term liabilities (A$92.0M).
Debt to Equity History and Analysis
Debt Level: TLX has more cash than its total debt.
Reducing Debt: TLX's debt to equity ratio has increased from 3.2% to 6.2% over the past 5 years.
Debt Coverage: TLX's debt is well covered by operating cash flow (260.4%).
Interest Coverage: TLX earns more interest than it pays, so coverage of interest payments is not a concern.